SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 11,455,882 shares of its common stock at a…
Thu, 01 May 2025 17:26:00 GMT NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units ...
Thu, 01 May 2025 17:26:00 GMT NEW YORK, May 02, 2025--(BUSINESS WIRE)--Cartesian Growth Corporation III (the "Company") announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 ...
Thu, 01 May 2025 17:00:00 GMT Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from ... This press release shall not constitute ...
Thu, 01 May 2025 07:51:00 GMT Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per ... 2025. This press release shall not constitute an offer to sell or the ...
Wed, 30 Apr 2025 17:00:00 GMT Cantor Equity Partners II, Inc. (Nasdaq: CEPT) (the “Company”) announced today the pricing of its upsized initial public offering of 24,000,000 Class A ordinary shares at $10.00 per share.
